These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7590825)

  • 1. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes.
    Melief CJ; Kast WM
    Immunol Rev; 1995 Jun; 145():167-77. PubMed ID: 7590825
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
    Matsui K; O'Mara LA; Allen PM
    Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immunotherapy.
    Manson LA
    Immunol Today; 1989 Feb; 10(2):36. PubMed ID: 2787650
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
    Huang H; Liu Y; Xiang J
    Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.
    Bai XF; Bender J; Liu J; Zhang H; Wang Y; Li O; Du P; Zheng P; Liu Y
    J Immunol; 2001 Oct; 167(7):3936-43. PubMed ID: 11564812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
    Zanovello P; Rosato A; Bronte V; Cerundolo V; Collavo D
    Ann Ist Super Sanita; 1991; 27(1):91-5. PubMed ID: 1958033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy through TCR gene transfer.
    Kessels HW; Wolkers MC; van den Boom MD; van der Valk MA; Schumacher TN
    Nat Immunol; 2001 Oct; 2(10):957-61. PubMed ID: 11577349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problem solving for tumor immunotherapy.
    Gouttefangeas C; Rammensee HG
    Nat Biotechnol; 2000 May; 18(5):491-2. PubMed ID: 10802611
    [No Abstract]   [Full Text] [Related]  

  • 10. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
    Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
    Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.
    Schmidt K; Keller C; Kühl AA; Textor A; Seifert U; Blankenstein T; Willimsky G; Kloetzel PM
    Cancer Res; 2018 Jun; 78(12):3243-3254. PubMed ID: 29559473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes].
    Kawakami Y
    Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2536-44. PubMed ID: 9922678
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12.
    Le HN; Lee NC; Tsung K; Norton JA
    J Immunol; 2001 Dec; 167(12):6765-72. PubMed ID: 11739491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo activation and retransfusion of white blood cells. The immunotherapy of cancer.
    Hamblin TJ
    Curr Stud Hematol Blood Transfus; 1990; (57):249-66. PubMed ID: 2272205
    [No Abstract]   [Full Text] [Related]  

  • 15. Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.
    Krause M; Schmitz M; Noessner E; Skrablin PS; Wehner R; Rieber EP; Baumann M
    Int J Radiat Biol; 2007; 83(11-12):827-36. PubMed ID: 17852560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.
    Riddell SR; Walter BA; Gilbert MJ; Greenberg PD
    Bone Marrow Transplant; 1994; 14 Suppl 4():S78-84. PubMed ID: 7728132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.